The goal of this study is to test the effect of a probiotic formulation on gastrointestinal symptoms, gut and small intestine microbiota in participants suffering from small intestinal bacterial overgrowth (SIBO). Two doses of probiotic will be evaluated against placebo.
Aged 18-65 years old at the inclusion of the study, both female and male subjects.
Signed Informed Consent; willing and able to comply with study procedures.
Willing to maintain their diet and physical activity levels during the study.
Able to swallow a size-00 capsule (23mm length and 9mm width).
History of less than three (3) bowel movements per week.
With the diagnosis of IBS-C.
Prior gastrointestinal disease, surgery, or abdominal or pelvic radiation treatment which, in the Investigator's opinion, would lead to intestinal structuring or obstruction with a risk of capsule non-excretion, including, e.g., achalasia, eosinophilic esophagitis, any IBD, or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months before the screening visit is acceptable.
Persons with central venous catheters.
Nimble Science Ltd.
Lead sponsor
Lallemand Health Solutions
Collaborator